Finance

Lists
Q3 2026 earnings • released • EPS beat +31.53% • Revenue beat +6.56%
See results
BIIB34:BVMF
Biogen Inc BDR
R$193.80
0.00%
(0.00) 1D
Oct 14, 12:51:04 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB34...
Mkt. cap
36.06B
Avg. vol.
8.00
Volume
0.00
52-wk high
R$193.80
52-wk low
R$132.99
Shares outstanding
147.75M
No. of employees
8K
Mkt. cap
36.06B
Avg. vol.
8.00
Volume
0.00
52-wk high
R$193.80
52-wk low
R$132.99
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com
Last report
Just released
Today, 2:30 PM
Fiscal period
Q3 2026
$2.62 / $1.99
+31.53%beat
Revenue / Est. (USD)
2.80B / 2.63B
+6.56%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.53B
2.28B
2.48B
2.74B
Cost of goods sold
508.60M
443.40M
610.20M
611.60M
Cost of revenue
508.60M
443.40M
610.20M
611.60M
Research and development expenses
431.80M
477.10M
482.20M
492.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
592.80M
685.20M
607.30M
709.70M
Operating expense
1.25B
1.36B
1.30B
1.44B
Total operating expenses
1.76B
1.81B
1.91B
2.05B
Operating income
778.60M
471.60M
567.40M
685.60M
Other non operating income
15.80M
17.40M
-1.10M
3.00M
EBT including unusual items
557.30M
-56.00M
377.70M
132.40M
EBT excluding unusual items
748.30M
447.00M
530.10M
625.10M
Income tax expense
90.80M
-7.10M
58.20M
34.90M
Effective tax rate
16.29%
12.68%
15.41%
26.36%
Other operating expenses
87.20M
69.90M
74.20M
68.80M
Net income
466.50M
-48.90M
319.50M
97.50M
Net profit margin
18.40%
-2.15%
12.89%
3.56%
Earnings per share
4.81
1.99
3.57
3.60
Interest and investment income
31.60M
37.20M
37.90M
25.30M
Interest expense
-67.40M
-67.50M
-67.60M
-82.30M
Net interest expenses
-35.80M
-30.30M
-29.70M
-57.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
980.80M
671.80M
771.80M
921.70M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps